46 1 Ning -spinal cord injury of C4-C5 (male, 26-year-old) - Before stem cell treatment Ning, a 26-year-old guy, happened to fall down from a high level in September, 2006, which led to his spinal cord injury of C4-C5 and remained quadriplegia, incontinence of urination and bowl... By: Stem Cells … Continue reading →

52 1 Mr. Wu -Lumbar Vertebra Injury (male, 22-year-old) - Before stem cell treatment Mr. Wu, 22 years old, happened to fall down on June 9th, 2011, which led to the 1st Lumbar vertebra injury. He received physical rehabilitation therapy after the injury, but the achieved improvemen... By: Stem Cells … Continue reading →

31 2 Mrs. Han -C4-C6 Spinal Cord Injury (Female, 39-year-old) - After stem cell treatment Mrs. Han, 39 years old, suffered from movement dysfunction, sensation disorder over 1 year after C4-C6 spinal cord injury. She received 1st round stem cell treatment in our hospital in November,... By: Stem Cells … Continue reading →

Baxter International Inc. said Thursday a key hemophilia drug under development met its primary goal in a late-stage clinical study. The drug, known as BAX 855, is essentially a stronger, extended-release version of its flagship hemophilia drug Advate, which is sold in dozens of countries around the world. The treatment is seen as a key part of the companys drug pipeline and its multibillion-dollar hemophilia franchise. The primary goal of the clinical trial was to show the drug reduces bleeding rates in patients administered the drug on a preventive basis versus with on-demand treatment. Deerfield-based Baxter, which raised its forecast for its hemophilia franchise last month, said BAX 855, when issued twice-weekly on a prophylactic, or preventive basis, resulted in a 95 percent reduction in annualized bleed rates. It is partnering with San Francisco-based Nektar Therapeutics on development of the treatment. Hemophilia A is a genetic disorder caused by certain missing or defective clotting agents in the blood. About 20,000 Americans suffer from the disorder, according to the National Hemophilia Foundation. Baxter said it plans to apply for approval to sell the drug from the U.S. Food and Drug Administration before the end of the year. It also said it … Continue reading →